3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
464
Neoplasms
287
Breast Neoplasms
287
Colorectal Neoplasms
201
Neoplasm Metastasis
178
Prostatic Neoplasms
165
Ovarian Neoplasms
159
Multiple Myeloma
153
Lung Neoplasms
150
Recurrence
125
Melanoma
116
Pancreatic Neoplasms
109
Stomach Neoplasms
99
Squamous Cell Carcinoma of Head and Neck
98
Leukemia, Myeloid, Acute
96
Endometrial Neoplasms
90
Leukemia, Lymphocytic, Chronic, B-Cell
87
Lymphoma, Non-Hodgkin
83
Small Cell Lung Carcinoma
82
Triple Negative Breast Neoplasms
81
Carcinoma, Renal Cell
78
Lymphoma, Large B-Cell, Diffuse
76
Carcinoma, Hepatocellular
75
Urinary Bladder Neoplasms
72
Lymphoma, Follicular
69
Advanced Solid Tumors
61
Parkinson Disease 4, Autosomal Dominant Lewy Body
60
Lymphoma
59
Glioblastoma
55
Uterine Cervical Neoplasms
51
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
High-Risk Localized Prostate Cancer
×
90 days
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled